Seven Eight Capital, LP Bei Gene, Ltd. Transaction History

Seven Eight Capital, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$215.53 - $274.5 $268,550 - $342,027	1,246 New	1,246 $268,000
Q2 2021 Aug 13, 2021	SELL	$292.75 - $367.01 $614,775 - $770,721	-2,100 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$221.31 - $316.61 $464,751 - $664,881	2,100 New	2,100 $543,000
Q1 2020 May 14, 2020	SELL	$121.84 - $173.19 $241,608 - $343,435	-1,983 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$115.78 - $208.34 $229,591 - $413,138	1,983 New	1,983 $329,000
Q3 2018 Oct 18, 2018	SELL	$152.62 - $189.66 $1.02 Million - $1.27 Million	-6,700 Closed	0 $0
Q2 2018 Aug 07, 2018	BUY	$152.5 - $216.77 $1.02 Million - $1.45 Million	6,700 New	6,700 $1.03 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.